Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
0.480
-0.003 (-0.52%)
At close: Feb 21, 2025, 4:00 PM
0.476
-0.004 (-0.85%)
After-hours: Feb 21, 2025, 5:23 PM EST
Leap Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
18.40M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
LPTX News
- 26 days ago - Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study - PRNewsWire
- 6 weeks ago - Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer - Seeking Alpha
- 6 weeks ago - Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference - PRNewsWire
- 3 months ago - Leap Therapeutics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 5 months ago - Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - PRNewsWire
- 6 months ago - Leap Therapeutics Reports Second Quarter 2024 Financial Results - PRNewsWire
- 10 months ago - Leap Therapeutics Reports First Quarter 2024 Financial Results - PRNewsWire